Attached files

file filename
EX-32.1 - EX-32.1 - Lyra Therapeutics, Inc.lyra-ex321_9.htm
EX-31.2 - EX-31.2 - Lyra Therapeutics, Inc.lyra-ex312_10.htm
EX-31.1 - EX-31.1 - Lyra Therapeutics, Inc.lyra-ex311_11.htm
10-Q - 10-Q - Lyra Therapeutics, Inc.lyra-10q_20200331.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Lyra Therapeutics, Inc. (the “Company”) for the period ended March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: May 28, 2020

 

By:

/s/ R. Don Elsey

 

 

 

R. Don. Elsey

 

 

 

Chief Financial Officer

(Principal Financial and Accounting Officer)